# Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction

> **NCT05191771** · NA · UNKNOWN · sponsor: **Horus Pharma** · enrollment: 120 (estimated)

## Conditions studied

- Dry Eye
- Meibomian Gland Dysfunction

## Interventions

- **DEVICE:** Neovis Total Multi
- **DEVICE:** Systane Balance

## Key facts

- **NCT ID:** NCT05191771
- **Lead sponsor:** Horus Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01
- **Primary completion:** 2022-10
- **Final completion:** 2022-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05191771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05191771, "Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05191771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*